What does private labeling look like in the FDA-regulated import world?
Attorney Benjamin L. England explains that private labeling has become increasingly common, particularly with the rise of e-commerce and global trade. Many U.S. companies today operate as virtual brands, outsourcing everything from manufacturing and labeling to logistics and warehousing. In this model, businesses primarily focus on branding and marketing while third parties handle the supply chain.
In FDA-regulated industries, private labeling is especially prevalent in heavily marketed and manufactured food categories, cosmetics, and other consumer products. Unlike whole foods such as fish or tomatoes, which are sold in raw form, branded and processed products often rely on private label arrangements where the brand owner may not physically touch the goods at all.
Who is legally responsible for compliance at the border in private label arrangements?
Benjamin clarifies that FDA’s jurisdiction centers on the entities performing regulated activities. The agency cares about who manufactures, packs, labels, or distributes the product—not simply whose name appears on the brand.
For example, a U.S. brand owner that does not engage in physical handling may fall outside FDA’s immediate focus. However, if the brand owner also serves as the importer, they take on legal responsibility for compliance at the border. Additionally, labeling rules require that either the manufacturer, packer, or distributor be identified on the product label. In cases where the distributor’s name is listed, the FDA and consumers will look to that company when problems arise.
What are the most common documentation and registration problems in private label relationships?
According to Benjamin, FDA facility registration is a frequent compliance gap. While some countries, such as Mexico or Canada, focus on product registration, the FDA requires facility registration for those engaged in regulated activities. Manufacturers, packers, and distributors are the primary entities FDA tracks, as these are the ones subject to inspection.
Certain industries, such as pharmaceuticals, impose specific requirements on private label distributors. For example, drug products require a National Drug Code (NDC) number, with the first five digits assigned to the labeler. In these cases, brand owners assume additional regulatory obligations even if they are not directly manufacturing the product.
Can manufacturers change a formula or label without telling the brand owner?
Benjamin notes that this problem does occur, particularly in industries with less FDA oversight at the pre-market stage, such as foods and cosmetics. Manufacturers may alter functional ingredients or modify labels without informing the private label distributor. Sometimes they fail to update the label at all, leading to misbranding or mislabeling violations.
In contrast, over-the-counter and prescription drug labeling is less vulnerable to these issues since FDA requires pre-market drug listings and NDC codes. Regardless of the industry, private label distributors face significant risk if they are unaware of formulation or labeling changes made by contract manufacturers.
What happens if a shipment is detained and the brand owner is not listed as the importer?
In these scenarios, the FDA will communicate only with the importer, owner, or consignee. If the brand owner is not one of these parties, they lose control over how issues are resolved at the border.
This creates potential risks where brand owners bear reputational and legal exposure but cannot influence the regulatory process. Benjamin advises brand owners to ensure they are formally included as either the importer, owner, or consignee. This ensures they can directly engage with FDA if problems arise, rather than relying on third parties to represent their interests.
How can private label distributors ensure labels and formulations meet FDA requirements if they don’t control the factory?
Benjamin emphasizes that contracts are the brand owner’s primary safeguard. Strong agreements should grant inspection rights, third-party audit authority, and pre-approval of labeling and formulations. Contracts should also include provisions for cost recovery if shipments are rejected or detained.
Neither FDA nor Customs will protect brand owners from supplier errors—compliance must be secured contractually. Without enforceable agreements, brand owners risk losing control over compliance and bearing financial responsibility for supplier mistakes.
What contract terms best protect brand owners from regulatory risks?
Benjamin recommends including clauses that allow on-site inspections, third-party audits, and mandatory compliance with U.S. regulatory requirements. Indemnification clauses are also important but have limits.
While manufacturers can agree to reimburse costs such as legal fees or replacement goods, brand owners cannot shift regulatory liability to suppliers. The FDA holds the importer responsible regardless of indemnification agreements. Therefore, contracts should focus on practical remedies while acknowledging that ultimate compliance responsibility rests with the U.S. importer.
Do most companies structure contracts up front or only after problems arise?
Benjamin observes that many companies wait until after compliance issues surface to formalize contracts. Often, international business is conducted informally through emails, WhatsApp messages, and price negotiations, with little attention given to regulatory obligations.
He warns that without clear written agreements, businesses rely on default legal terms that may not protect their interests. When problems occur, the lack of contracts leads to disputes, damaged relationships, and financial loss. He stresses that contracts are essential even among trusted partners, as they preserve both business relationships and personal friendships when challenges arise.
What advice does Benjamin offer to new U.S. brands considering overseas private label sourcing?
Benjamin advises new brand owners to partner with manufacturers who already have FDA compliance experience and established U.S. operations. While experienced suppliers may cost more, they significantly reduce the risk of regulatory problems.
He also recommends checking whether potential partners are on FDA’s publicly available import alert list. Performing due diligence, reviewing a supplier’s regulatory history, and confirming their familiarity with FDA requirements are critical steps before entering into a contract manufacturing arrangement.
If you’re facing challenges with importing FDA-regulated products, we’re here to help you navigate the process smoothly. Let us be your guide through the complexities of trade tariffs, FDA compliance, and border issues. Visit us at FDAImports or contact us directly at contact@fdaimports.com for assistance.
This news update is provided for informational and educational purposes only and does not constitute legal advice and is not intended to form an attorney-client relationship. Please contact your regular FDAImports representative for additional information.
